• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»Abbott Laboratories

Can Dexcom G7 reshape CGM adoption for type 2 diabetes patients not using insulin?

By Pallavi Madhiraju on June 7, 2026   Medical Devices & Diagnostics  

Can Dexcom G7 reshape CGM adoption for type 2 diabetes patients not using insulin?

Find out how Dexcom G7 data could reshape CGM adoption for type 2 diabetes patients not using insulin.

Is Abbott building the next integrated platform for complex heart rhythm treatment?

By Pallavi Madhiraju on April 26, 2026   Medical Devices & Diagnostics  

Is Abbott building the next integrated platform for complex heart rhythm treatment?

Abbott has PFA momentum, but rhythm care is becoming a platform battle. Can clinical data turn into durable adoption?

Recent Posts

  • Could KARL STORZ’s Rubina Lens turn open surgery into the next imaging battleground?
  • Elixiron’s oral Alzheimer’s drug data raise a bigger question: can neuroinflammation become the next serious treatment target?
  • Apnimed advances oral OSA therapy case as AD109 heads toward FDA decision window
  • Optimi Health’s first UK psilocybin export signals bigger test for GMP psychedelic manufacturing
  • Why Cartesian Therapeutics’ WestGene pact could intensify the race for autoimmune cell therapy
  • Why FDA alignment could move Alterity’s ATH434 closer to a pivotal MSA test
  • Why TG Therapeutics’ BRIUMVI data could open a new treatment path in myasthenia gravis
  • Harbour BioMed’s HBM7004 China IND acceptance sharpens the race for B7-H4 cancer targets
  • Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets
  • Can Zetagen’s ZetaMet Phase 2a data change how metastatic breast cancer bone lesions are treated?
  • Why Lilly’s expanded Ebglyss label could reset dosing expectations in atopic dermatitis biologics
  • Enveric Biosciences’ EB-003 push highlights the next battle in neuroplastogen drug development
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes